Shares of Biogen Idec (Nasdaq: BIIB) are seeing pressure in early trade Wednesday following FDA approval of Novartis' (NYSE: NVS) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE